Diopsys NOVA: Modified Equipment, Unnecessary Testing and Contingent Payments

Whistleblower Justice Network

In the Diopsys NOVA False Claims Act settlement, Diopsys agreed to pay up to $14.25 million over allegations that it modified vision-testing equipment without required Food and Drug Administration clearance and promoted medically unnecessary tests billed to Medicare and Medicaid. The case reached inside the sales pitch: what the machine could do, which tests doctors should order, and how much each patient could bring the practice.

The Department of Justice announced the settlement on March 27, 2025. A California ophthalmologist brought the whistleblower case against the medical device company, based in Middletown, Pennsylvania. Most of the potential settlement depends on the company’s future revenue.

What Changed in the NOVA System

The government alleged that Diopsys turned a medical device cleared for visual evoked potential testing into one marketed for electroretinography without seeking the required new clearance. Those tests measure different things. As the ophthalmologist’s complaint explains, VEP records the brain’s response to visual stimulation, while ERG measures the retina’s electrical response to light.

The settlement agreement’s account of the government’s allegations supplies the changes behind that distinction. Diopsys obtained clearance for VEP testing around May 9, 2011. By June 2012, it allegedly had substantially modified NOVA to enable ERG testing. Over time, it added full-field, pattern and multifocal ERG tests. Sales representatives described the ERG features as “completely new,” and internal records referred to new electrodes and a new manufacturing process.

The government alleged that Diopsys knew, or was reckless in not knowing, that the changes required Food and Drug Administration review. Its sales personnel allegedly promoted the equipment for medically unnecessary uses and explained how doctors could maximize their financial return.

The complaint identified a discrepancy in the product name itself. It alleged that Diopsys marketed the “Diopsys NOVA ERG and VEP Vision Testing System,” while the cleared name was “Diopsys NOVA VEP Vision Testing System.” Adding ERG to the sales description allegedly implied that the clearance covered the added function.

The whistleblower also challenged the Diopsys ERG Lid Sensor, an electrode placed on the eyelid. The complaint alleged that it had not been extensively studied or evaluated or approved by the Food and Drug Administration. The sensor, the manufacturing changes and the product name all bear on the same question: what equipment was the customer actually being sold?

How the Testing Became Medicare and Medicaid Claims

The alleged sales strategy joined the test recommendation to the expected payment. According to the complaint, Diopsys promoted tests that took one minute, could be repeated at each visit and could bring more than $300 per eye per day. It allegedly encouraged providers to bill all three ERG procedure codes, sometimes alongside VEP testing, and to test each eye on separate days to increase reimbursement and avoid detection of overuse.

The complaint describes an Excel workbook called “Clinical Utilization Worksheet for Visual Electrophysiology.” It allegedly supplied clinical indications, diagnosis codes and expected reimbursement in the same worksheet. The whistleblower alleged that glaucoma-related descriptions appeared under other names, including “RNFL abnormality” and “RNFL defect,” to support billing for tests that should not have been billed for glaucoma.

In the complaint’s account, that worksheet put the manufacturer’s advice directly into the practice’s testing and billing decisions. The alleged recommendation arrived with both a reason to order the test and the anticipated return from billing it.

The complaint also recounts a sales demonstration involving seven patients. It quotes the representative’s follow-up pitch:

that represents more than $1000 in incremental revenue, not to mention the beneficial diagnostic information to help you better manage your patient’s treatments. The longer you delay, the larger the dollar amount of missed profits.

Sales representative’s words quoted in the whistleblower’s complaint, United States ex rel. Jain v. Diopsys, Inc., paragraph 51

The whistleblower linked that promotion to a broader increase in testing, alleging that Medicare ERG claims rose 25-fold between 2012 and 2018 and attributing much of the increase to Diopsys’s marketing and physicians’ pursuit of testing revenue. The government’s settlement allegations followed the commercial chain from manufacturer promotion to physician decisions to claims submitted to federal and state health care programs. In that account, Medicare and Medicaid were billed for testing patients did not need.

Why FDA Clearance and Medicare Payment Are Different

The NOVA allegations concerned both what Diopsys sold and what the practice billed. Clearance to market the equipment and Medicare payment for a patient’s test are separate decisions.

In the complaint’s account, the product name implied clearance for an added testing function, and the utilization worksheet paired test recommendations with billing codes. The government’s agreement then alleged that Diopsys’s promotion caused physicians to submit false claims for unnecessary testing. The request for government money came from the practice using the machine.

What the Diopsys Settlement Requires

The fixed payment is $1,225,000.

Up to $13,025,000 more depends on Diopsys’s revenue. The agreement ties those payments to gross revenue, with percentages from 5% to 20%. The Justice Department said the settlement reflected Diopsys’s financial condition.

What Evidence Is Needed to Prove Fraud?

We work with medical device and practice insiders to connect what they know about the machine and the sales advice to the tests performed and the claims submitted. The Diopsys complaint points to specific material a medical device or practice insider would recognize: the product description, the eyelid sensor, the utilization worksheet and the representative’s sales pitch. The agreement adds internal records about electrodes and manufacturing changes.

A related pattern appeared in PenRad Technologies’ breast-screening software case. The government alleged that mammography software installed with its competing-mortality setting disabled led to recommendations for unnecessary MRIs. PenRad’s own customer brought that whistleblower case. The setting inside the product helped explain the testing decisions downstream.

In a medical device case, someone who knows the configuration can explain what the equipment actually did. Someone who saw the customer instructions can explain how the manufacturer encouraged its use. We bring that product knowledge and healthcare billing expertise together to build the case with you.

How Much Does a Medicare Fraud Whistleblower Get Paid?

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. In the Diopsys case, the agreement assigns the ophthalmologist about 19% of each federal settlement payment received by the government.

You Know How the Test Was Sold

If you know how a medical device’s sales pitch became a practice’s testing routine, speak with our whistleblower experts about how the test was sold. We build the case with you, bring in medical device fraud whistleblower lawyers who understand manufacturer promotion and Medicare billing, and stay beside you through the pursuit of a recovery.

WHISTLEBLOWER JUSTICE NETWORK CAN HELP YOU
Make a difference.
Whistleblower Justice NetworkReport Fraud
100% CONFIDENTIALFREE CONSULTATION24 / 7 / 365